Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CORVUS PHARMACEUTICALS, INC.

(CRVS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
5.31(c) 5.15(c) 5.04(c) 5.13(c) 4.95 Last
4 113 270 1 263 368 512 191 1 331 398 1 202 538 Volume
+12.98% -3.01% -2.14% +1.79% -3.51% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -40,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,16x
Yield 2021 -
Sales 2022 34,1 M - -
Net income 2022 -41,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -7,33x
Yield 2022 -
Capitalization 218 M 218 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 6,38x
Nbr of Employees 42
Free-Float 88,4%
More Financials
Company
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site... 
More about the company
Ratings of Corvus Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about CORVUS PHARMACEUTICALS, INC.
09/22Health Care Stocks Follow Market Higher Wednesday
MT
09/22Health Care Stocks Edge Higher Premarket Wednesday
MT
09/22CORVUS PHARMACEUTICALS : Reports Results of Phase 3 Trial of Mupadolimab; Shares Fall Pre-..
MT
09/22Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology..
GL
09/22Corvus Pharmaceuticals Provides Updates on Mupadolimab
CI
09/17Top Premarket Gainers
MT
09/07Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
GL
08/17CORVUS PHARMACEUTICALS : Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-1 i..
AQ
08/17CORVUS PHARMACEUTICALS' : Chinese Partner Gets Regulatory Nod to Conduct Early Stage Study..
MT
08/16CORVUS PHARMACEUTICALS' : Application for Phase 1 Clinical Trial Accepted by Chinese Regul..
MT
08/16CORVUS PHARMACEUTICALS : Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818..
AQ
08/03CORVUS PHARMACEUTICALS : Provides Business Update and Reports Second Quarter 2021 Financia..
AQ
08/03CORVUS PHARMACEUTICALS : Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals ..
MT
08/03CORVUS PHARMACEUTICALS : Mizuho Securities Adjusts Corvus Pharmaceuticals' Price Target to..
MT
08/03CORVUS PHARMACEUTICALS : Provides Business Update and Reports Second Quarter 2021 Financia..
PU
More news
News in other languages on CORVUS PHARMACEUTICALS, INC.
09/22Les actions du secteur de la santé suivent la hausse du marché mercredi
09/22Corvus Pharmaceuticals publie les résultats de l'essai de phase 3 sur le mupadolimab ; ..
More news
Analyst Recommendations on CORVUS PHARMACEUTICALS, INC.
More recommendations
Chart CORVUS PHARMACEUTICALS, INC.
Duration : Period :
Corvus Pharmaceuticals, Inc. Technical Analysis Chart | CRVS | US2210151005 | MarketScreener
Technical analysis trends CORVUS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 4,95 $
Average target price 5,13 $
Spread / Average Target 3,54%
EPS Revisions
Managers and Directors
Richard A. Miller Chairman, President & Chief Executive Officer
Leiv Lea Chief Financial Officer
Suresh Mahabhashyam Vice President-Clinical Development
Peter A. Thompson Independent Director
Elisha P. Gould Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CORVUS PHARMACEUTICALS, INC.39.04%218
MODERNA, INC.210.34%133 962
LONZA GROUP AG26.44%57 839
IQVIA HOLDINGS INC.38.89%47 294
SEAGEN INC.-1.38%30 963
CELLTRION, INC.-38.72%25 574